More on Bristol-Myers (BMY) Q2: net profit -28% to $645M as patent expirations for Plavix,...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

More on Bristol-Myers (BMY) Q2: net profit -28% to $645M as patent expirations for Plavix, Avapro and Avalide take their toll, although sales of other drugs rise. U.S. sales -27% to $2.6B, non-U.S. -1% to $1.9B. Cuts FY EPS guidance to $1.78-1.88 from $1.90-2 prior; keeps adjusted EPS forecast at $1.90-2 vs. consensus of $1.94.